Nautilus Biotechnology (NAUT) Operating Expenses (2020 - 2026)

Nautilus Biotechnology has disclosed Operating Expenses across 7 years of filings, most recently posting $16.1 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $16.1 million, down 14.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $64.1 million (down 18.54% YoY), and the FY2025 annual result was $66.8 million, down 17.97% from the prior year.
• Operating Expenses came in at $16.1 million for Q1 2026 at Nautilus Biotechnology, up from $15.4 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $21.6 million in Q1 2024 to a low of $15.4 million in Q4 2025.
• The 5-year median for Operating Expenses is $18.1 million (2023), against an average of $17.9 million.
• Across the five-year window, Operating Expenses surged 90.35% in 2022 and decreased 22.8% in 2025, its largest moves.
• Nautilus Biotechnology's Operating Expenses stood at $16.3 million in 2022, then grew by 22.68% to $20.0 million in 2023, then decreased by 0.1% to $20.0 million in 2024, then fell by 22.8% to $15.4 million in 2025, then increased by 4.54% to $16.1 million in 2026.
• The last three Operating Expenses figures came in at $16.1 million (Q1 2026), $15.4 million (Q4 2025), and $15.5 million (Q3 2025), per Business Quant data.